UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 176

Sortiert nach

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Haematologica (Roma), 2021-06, Vol.106 (6), p.1559

2021

Volltextzugriff (PDF)

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

Leukemia, 2020-10, Vol.34 (10), p.2813-2814

2020

Volltextzugriff (PDF)

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

Leukemia, 2020-10, Vol.34 (10), p.2805-2808

2020

Volltextzugriff (PDF)

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study

Haematologica (Roma), 2016-12, Vol.101 (12), p.1544

2016

Volltextzugriff (PDF)

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

Leukemia, 2020-09, Vol.34 (9), p.2451-2459

2020

Volltextzugriff (PDF)

IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5202-5207

2009

Volltextzugriff (PDF)

Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies

Quality of life research, 2020-03, Vol.29 (3), p.815-823

2020

Volltextzugriff (PDF)

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5397-5403

2009

Volltextzugriff (PDF)

Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell’Adulto

Journal of clinical oncology, 2001-10, Vol.19 (20), p.4023-4028

2001

Volltextzugriff (PDF)

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Frontiers in oncology, 2022-03, Vol.12, p.826040-826040

2022

Volltextzugriff (PDF)

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

Clinical cancer research, 2009-08, Vol.15 (15), p.5002-5007

2009

Volltextzugriff (PDF)

Regulation 536/2014 and its beneficial impacts on academic clinical research in Italy. Closing the loop

Contemporary clinical trials communications, 2022-10, Vol.29, p.100992-100992, Article 100992

2022

Volltextzugriff (PDF)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey

Journal of clinical medicine, 2023-08, Vol.12 (16), p.5267

2023

Volltextzugriff (PDF)

Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients

EJHaem, 2024-04, Vol.5 (2), p.353-359

2024

Volltextzugriff (PDF)

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

HemaSphere, 2023-08, Vol.7 (S3), p.e4536536-n/a

2023

Volltextzugriff (PDF)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

HemaSphere, 2023-08, Vol.7 (S3), p.e997112b-n/a

2023

Volltextzugriff (PDF)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST‐CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e8415389-n/a

2023

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(163)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(95)
Humans
(72)
Hematology
(61)
Male
(46)
Female
(45)
Middle Aged
(44)
Adult
(37)
Biological And Medical Sciences
(35)
Medical Sciences
(31)
Oncology
(27)
Aged
(25)
Hematologic And Hematopoietic Diseases
(23)
Adolescent
(22)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(22)
Treatment Outcome
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Remission Induction
(18)
Prognosis
(16)
Leukemia
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(71)
Haematologica
(9)
Journal Of Clinical Oncology
(9)
British Journal Of Haematology
(8)
Blood Advances
(7)
Leukemia
(6)
American Journal Of Hematology
(5)
Hemasphere
(4)
European Journal Of Cancer & Clinical Oncology
(3)
Cancers
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study

Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell’Adulto

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

Regulation 536/2014 and its beneficial impacts on academic clinical research in Italy. Closing the loop

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW‐RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD

Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST‐CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

Suchergebnisse filtern